Menu
Curie Logo
Donate
  • Home

Clinical trials - page 3

Essais cliniques
Search for a clinical trial
Filter

195 result(s)

  • Paris, Saint-Cloud
    ALCYTA (IC 2020-12)
    Exploration of Adaptive Antitumoral Immune Cells Through Leukapheresis in Cancer Patients: ALCYTA

    NICOLAS GIRARD

  • Saint-Cloud
    ALPHABET
    Randomized phase III trial of the administration of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with a PIK3CA mutation and previously treated for advanced HER2+ cancer

    FRANCOIS-CLEMENT BIDARD

  • Saint-Cloud
    AMEBICA - Prodige 38
    Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours.

  • Saint-Cloud
    AML LI-1
    A PROGRAMME OF DEVELOPMENT FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME

    JACQUES VARGAFTIG

  • Saint-Cloud
    APACaP
    Multicenter, Randomized Study, Evaluation of Adapted Physical Activity Program in Patients With Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

  • Eye tumors / Uveal melanoma
    Paris
    ATOM
    Adjuvant tebentafusp (IMCgp100) versus observation in HLA-A*02:01positive patients following definitive treatment of high-risk uveal melanoma: an EORTC randomized phase III study;(ATOM Trial)

    MANUEL RODRIGUES

  • ENT/Head and Neck Cancers
    Paris
    AV-299-23-301
    A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF FICLATUZUMAB IN COMBINATION WITH CETUXIMAB IN PARTICIPANTS WITH RECURRENT OR METASTATIC (R/M) HPV-NEGATIVE HEAD AND NECK SQUAMOUS CELL CARCINOMA (FIERCE-HN)

    EDITH BORCOMAN

  • Saint-Cloud
    AcSé Pembrolizumab
    Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types.

    CAROLE SOUSSAIN

  • Saint-Cloud
    AcSé Vemurafenib
    Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

    ETIENNE BRAIN

  • Lung cancer
    Paris
    BAYER 22615 (SOHO 02)
    A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations.

    NICOLAS GIRARD

  • Sarcomas
    Paris
    BFR ESS 01
    Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS

    SOPHIE PIPERNO-NEUMANN

  • Breast cancer
    Paris
    BGB-43395-101
    Phase Ia/Ib study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the CDK4 inhibitor BGB-43395 as monotherapy and in combination with other treatments in patients with HR+/HER2- metastatic breast cancer and other advanced solid tumors.

    MARIE PAULE SABLIN

  • Paris
    BGB-58067-101 (PRMT5i)
    The BGB-58067-101 study is a Phase 1a/1b clinical trial evaluating BGB-58067, a selective MTA-cooperative PRMT5 inhibitor, in patients with advanced solid tumors harboring homozygous MTAP deletion.

    CHRISTOPHE LE TOURNEAU

  • Bladder cancer
    Paris
    BLAD-RAD01 (GETUG-AFU V07)
    Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy: a Prospective Randomized Comparative Phase II Trial.

    GILLES CREHANGE

  • Saint-Cloud
    BLOCAGE 01
    Phase III Trial Evaluating Maintenance Treatment Versus Observation in Elderly Patients Suffering From Primary Central Nervous System Lymphoma in Complete Remission After High Dose Methotrexate Based Chemotherapy in First Line

    CAROLE SOUSSAIN

  • ENT/Head and Neck Cancers
    Paris
    BNT113-01
    A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

    CHRISTOPHE LE TOURNEAU

  • Saint-Cloud
    BO25430
    AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB EMTANSINE ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN-LA ROCHE LTD·SPONSORED TRASTUZUMAB EMTANSINE STUDY.

    FLORENCE LEREBOURS

  • Breast cancer
    Paris
    BRAINSTORM
    A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours - BrainStorm Program

    EDITH BORCOMAN

  • Saint-Cloud
    BYLieve (CBYL719X402)
    A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment

    FLORENCE LEREBOURS

  • Leukemia
    Saint-Cloud
    Backbone Inter-Group-1 (BIG-1)
    Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial

    JACQUES VARGAFTIG

  • Lymphoma
    Saint-Cloud
    CA-4948-101
    An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphom.

    CAROLE SOUSSAIN

  • Lymphoma
    Saint-Cloud
    CA073-1020
    A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

    CLEMENTINE SARKOZY

  • Hématologie / cancers du sang
    Saint-Cloud
    CA073-1022
    Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced-Stage Follicular Lymphoma (GOLSEEK-2)"

    CLEMENTINE SARKOZY

  • Paris
    CA245-0001
    Phase 3, randomized, double-blind, multicenter study evaluating the combination of BMS-986489 (a fixed-dose combination of Nivolumab and BMS-986012) with carboplatin and etoposide versus the combination of Atezolizumab with carboplatin and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer (ES-SCLC).

    NICOLAS GIRARD

  • Breast cancer
    Saint-Cloud
    CAAA603B12101 NeoB
    Phase Ib Dose Finding Study Assessing Safety and Activity;of [;177Lu]LuNeob in combination with ribocilcib and fulvestrant;in subjects with HR positive, HER2 negative breast cancer,;experiencing early relapse from (neo)adjuvant endocrine;therapy.

    CAPUCINE RICHARD

  • Cancers urogénitaux
    Paris, Saint-Cloud
    CAAA617D12302
    A prospective, multicenter, open-label, randomized international Phase III study evaluating treatment with lutetium (177Lu) vipivotide tetraxetan (AAA617) versus surveillance alone to delay the need for castration or disease recurrence in adult male patients with PSMA-positive oligometastatic prostate cancer.

    CAPUCINE RICHARD

  • Saint-Cloud
    CANTO (Saint-Cloud)
    A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer

    FLORENCE LEREBOURS

  • Saint-Cloud
    CANTO BIS
    A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer.

    FLORENCE LEREBOURS

  • Breast cancer
    Paris, Saint-Cloud
    CAPPA
    Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery (CAPPA).

    DELPHINE LOIRAT

  • Paris
    CINNAMON
    Evaluation of the quality of life induced by the anti-odor cinnamon dressing in patients with malodorous wounds: a multicenter randomized controlled trial.

<
1 ...3...7
>